 LONDON and NEW YORK, May 26, 2021 PRNewswire -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies Urovant, Enzyvant, Altavant and Spirovant and Myovant Sciences NYSE: MYOV, a publicly listed company that is majority owned by Sumitovant, achieved significant clinical and corporate milestones in the companys fourth quarter ending on March 31, 2021. Sumitovant Biopharma Has a Strong Fourth Quarter Across its Portfolio of Companies We were delighted to see tremendous strides across the Sumitovant portfolio of companies in the fourth quarter including progress across clinical development, regulatory and commercialization milestones. 